SHINE Medical Technologies Therapeutics division has made its first commercial sale of lutetium-177, a therapeutic isotope in demand by clinical trial sponsors, the company announced recently. “This milestone is really exciting,…
Exact Sciences announced today it will acquire Thrive Earlier Detection Corp. for $2.15 billion and Base Genomics for an undisclosed sum. Both companies specialize in cancer screening blood tests. According to…
Exact Sciences has introduced its Oncotype MAP Pan-Cancer Tissue test for patients with advanced, metastatic, refractory or recurrent cancer, the company announced today. According to a release, the Oncotype MAP…
Exact Sciences has extended and made amendments to its agreement with Pfizer to promote Cologuard, the company announced recently. “We’re thrilled to continue working with Pfizer to increase screening rates with…
Nimble Therapeutics has entered into a strategic collaboration with Incyte, a pharmaceutical company, to discover first-in-class peptide therapies across various disease areas, the company announced recently. “This is an important…
OnLume has been awarded a $2 million grant from the U.S. National Institutes of Health’s National Cancer Institute to advance the development of its proprietary device for Fluorescence-Guided Surgery (FGS),…
SHINE Medical Technologies has closed an $80 million Series C financing round, the company announced recently. “This funding round will help SHINE’s continuing efforts to commercialize vital diagnostic and therapeutic…
The problem with current opioid use disorder (OUD) medication-assisted treatment is that in between doses, individuals are more likely to relapse because they must willingly choose to take their next…
Propeller Health announced today it will begin distributing in Japan through collaboration with Novartis by connecting Propeller’s digital health platform to two of Novartis’ medications. According to a release, Enerzair Breezhaler…
NorthStar Medical Radioisotopes, along with Wilmette, Ill.-based Monopar Therapeautics, have partnered with IsoTherapeutics Group to develop and manufacture Radio-Immuno-Therapeutics (RITs) for the potential treatment of severe COVID-19, the company announced recently….
